ImmuPharma plc (LON:IMM – Get Free Report) was up 27.6% on Saturday . The stock traded as high as GBX 3.60 ($0.04) and last traded at GBX 3.35 ($0.04). Approximately 8,992,934 shares changed hands during mid-day trading, a decline of 61% from the average daily volume of 23,308,711 shares. The stock had previously closed at GBX 2.63 ($0.03).
ImmuPharma Stock Performance
The business’s fifty day simple moving average is GBX 1.59 and its 200 day simple moving average is GBX 1.69. The stock has a market cap of £13.95 million, a price-to-earnings ratio of -335.00 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Recommended Stories
- Five stocks we like better than ImmuPharma
- What Are the FAANG Stocks and Are They Good Investments?
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- Stock Analyst Ratings and Canadian Analyst Ratings
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- Why Invest in 5G? How to Invest in 5G Stocks
- MarketBeat Week in Review – 01/13 – 01/17
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
